Developer Submits BLA for TLX250-CDx Kidney Cancer Imaging in ccRCC
TLX250-CDx elicited a mean sensitivity of 85.5% and a mean specificity of 87.0% in patients with indeterminate renal masses in the phase 3 ZIRCON trial.
Related Articles
Victoria’s Secret Global Fund for Women’s Cancers Rising Innovator Research Grants, in Partnership with Pelotonia & AACR
$700,000 over three years for female associate professors performing research that has a direct applicability and relevance to the understanding, prevention, interception, early detection, diagnosis,…
Recent Advances in Fabry Disease Clinical Research
David Warnock, MD, Professor of Medicine (Emeritus), University of Alabama at Birmingham, discusses recent advances in Fabry disease.
SBRT/Concurrent Chemoradiotherapy Shows Favorable Activity in NSCLC
Although not hitting its primary end point, a phase 2 trial showed that SBRT plus concurrent radiotherapy improved on results elicited in other trials.
Upcoming FDA-AACR Workshop Will Discuss DPD Deficiency Testing
A FDA-AACR workshop will discuss the considerations for DPD deficiency testing before chemotherapy with fluoropyrimidines.
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
Scientists in Seattle make progress on a cure for Genital Herpes
Scientists at the Fred Hutchinson Cancer Center say they’re making progress on a cure for Genital herpes.
Leonard and Norma Klorfine Endowed Chair for Clinical Research awarded to Dr. Geoffrey Hill
Geoffrey Hill, MD, FRACP, FRCPA, was recently announced as the recipient of the Leonard and Norma Klorfine Endowed Chair for Clinical Research at Fred Hutch…
Program: Sunday, February 23
sunday, february 23 *-Short talk from proffered abstract registration 12-9 p.m. EDUCATIONAL SESSIONS 1 AND 2 3:30-4:50 p.m. educational session 1: detection of tumor-reactive t…
Dana-Farber Launches Center for RAS Therapeutics to Target the RAS Oncogene in Cancer
Dana-Farber Cancer Institute will launch the Center for RAS Therapeutics to advance scientific investigation and clinical care for RAS-driven cancers.
Dissemination and Implementation – A Primer for Accelerating “Time to Translation” in Radiation Oncology
The field of radiation oncology has achieved significant technological and scientific advancements in the 21st century. Yet uptake of new evidence-based practices has been heterogeneous,…
